1-2 of 2
Marc Weimer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial

Hans-Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, Marc Weimer, Thomas Meinicke, Uli C. Broedl, Hans J. Woerle, on behalf of the EMPA-REG MET Trial Investigators
Journal: Diabetes Care
Diabetes Care 2014;37(6):1650–1659
https://doi.org/10.2337/dc13-2105
Published: 10 May 2014
View articletitled, Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial
Open the PDF for Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial in another window
Includes: Supplementary data
Journal Articles

Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial

Hans-Ulrich Häring, MD, Ludwig Merker, MD, Elke Seewaldt-Becker, PHD, Marc Weimer, PHD, Thomas Meinicke, MD, Hans J. Woerle, MD, Uli C. Broedl, MD, on behalf of the EMPA-REG METSU Trial Investigators
Journal: Diabetes Care
Diabetes Care 2013;36(11):3396–3404
https://doi.org/10.2337/dc12-2673
Published: 15 October 2013
View articletitled, Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial
Open the PDF for Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial in another window
Includes: Supplementary data